Venous thromboembolism following L-asparaginase treatment for lymphoid malignancies in Korea
- PMID: 28150907
- DOI: 10.1111/jth.13636
Venous thromboembolism following L-asparaginase treatment for lymphoid malignancies in Korea
Abstract
Essentials Data on venous thromboembolism (VTE) after L-asparaginase (L-asp) in Asian lymphoma are scarce. This is a population-based study in Asian patients with lymphoid disease and L-asp-related VTE. The overall incidence of L-asp-associated VTE was similar to reports on Caucasians. This first and largest study in Asians shows that mainly adult patients are at risk of thrombosis.
Summary: Background L-asparaginase (L-asp)-associated venous thromboembolism (VTE) is a serious adverse complication associated with acute lymphoblastic leukemia (ALL) and lymphoma treatment. The incidence rate of L-asp-related VTE in Asian cancer patients is not well known. Methods We performed a population-based study between 2009 and 2013 using claim databases, including both diagnostic and medication codes, such as anti-cancer treatment with L-asp and VTE diagnoses from the starting date until 3 months after cessation of L-asp. Results A total of 3286 patients were prescribed L-asp treatment for any type of lymphoid malignancy including ALL and lymphoma; 116 patients (3.5%) experienced VTE. The most common site of thrombosis was the upper extremities (34.5%). Cerebral vein thrombosis (1.7%) occurred in two pediatric patients; 2.4% (43/1795) of pediatric patients and 4.9% (72/1486) of adult patients suffered from VTE, respectively; 2.7% (56/2064) of ALL and 4.9% (59/1217) of lymphoma patients were diagnosed with VTE after L-asp exposure. After univariate analysis, both the diagnosis of lymphoma (vs. ALL) and being an adult patient (vs. pediatric patient) were risk factors for VTE occurrence. However, after multivariate analysis, only age > 18 remained a risk factor for VTE (odds ratio, 1.79; 95% confidence interval, 1.14-2.81). Conclusions This is the first and largest population-based study in Asian patients with lymphoid malignancies treated with L-asp demonstrating that adult patients are at elevated risk of thrombosis after L-asp exposure. The overall incidence of L-asp-related VTE amongst these patients was similar to that in Caucasian populations.
Keywords: Asian; L-asparaginase; acute lymphoblastic leukemia; lymphoma; venous thromboembolism.
© 2017 International Society on Thrombosis and Haemostasis.
Similar articles
-
Venous thromboembolism incidence associated with pegylated asparaginase (ASP) compared to the native L-ASP: A retrospective analysis with an ASP-based protocol in adult patients with acute lymphoblastic leukaemia.Br J Haematol. 2023 May;201(4):645-652. doi: 10.1111/bjh.18683. Epub 2023 Feb 16. Br J Haematol. 2023. PMID: 36794878
-
Venous thromboembolism incidence and risk factors in adults with acute lymphoblastic leukemia treated with and without pegylated E. coli asparaginase-containing regimens.Cancer Chemother Pharmacol. 2021 Jun;87(6):817-826. doi: 10.1007/s00280-021-04252-y. Epub 2021 Mar 7. Cancer Chemother Pharmacol. 2021. PMID: 33677674
-
L-asparaginase and venous thromboembolism in acute lymphocytic leukemia.Future Oncol. 2015;11(17):2459-70. doi: 10.2217/fon.15.114. Epub 2015 Aug 14. Future Oncol. 2015. PMID: 26274336 Free PMC article. Review.
-
The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols.Br J Haematol. 2011 Feb;152(4):452-9. doi: 10.1111/j.1365-2141.2010.08524.x. Epub 2011 Jan 7. Br J Haematol. 2011. PMID: 21210774 Free PMC article.
-
Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia.Cochrane Database Syst Rev. 2020 Oct 10;10(10):CD013399. doi: 10.1002/14651858.CD013399.pub2. Cochrane Database Syst Rev. 2020. PMID: 33038027 Free PMC article.
Cited by
-
Prevalence and Risk Factors of L-Asparaginase-Related Thrombosis Among Acute Lymphoblastic Lymphoma Patients in a Resource-Limited Setup of Sub-Saharan Region.Cancer Rep (Hoboken). 2025 Mar;8(3):e70153. doi: 10.1002/cnr2.70153. Cancer Rep (Hoboken). 2025. PMID: 40047199 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources